Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GERN Geron Corp
- Stocks
- Healthcare
- NASDAQ: GERN
Price (delayed)
$1.55
Market cap
$987.22M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.21
Enterprise value
$1.15B
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two
Highlights
The quick ratio has soared by 90% YoY and by 36% from the previous quarter
The revenue has soared by 51% from the previous quarter
GERN's debt has surged by 186% year-on-year
Geron's equity has decreased by 22% YoY and by 4.3% from the previous quarter
Key stats
What are the main financial stats of GERN
Market
Valuations
Earnings
Shares outstanding
636.92M
Market cap
$987.22M
Enterprise value
$1.15B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.68
Price to sales (P/S)
8.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.88
Revenue
$116.29M
Gross profit
$113.83M
Operating income
-$134.3M
Net income
-$139.02M
EBIT
-$115.75M
EBITDA
-$114.49M
Free cash flow
-$204.38M
Per share
Balance sheet
Liquidity
EPS
-$0.21
EPS diluted
-$0.21
Free cash flow per share
-$0.31
Book value per share
$0.42
Revenue per share
$0.17
TBVPS
$0.84
Total assets
$562.45M
Total liabilities
$294.21M
Debt
$247.69M
Equity
$268.24M
Working capital
$432.74M
Debt to equity
0.92
Current ratio
7.87
Quick ratio
6.86
Net debt/EBITDA
-1.42
Margins
Efficiency
Dividend
EBITDA margin
-98.5%
Gross margin
97.9%
Net margin
-119.5%
Operating margin
-115.5%
Return on assets
-27.1%
Return on equity
-48.5%
Return on invested capital
-23.4%
Return on capital employed
-23.2%
Return on sales
-99.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GERN stock price
How has the Geron stock price performed over time
Intraday
2.65%
1 week
-4.32%
1 month
22.05%
1 year
-68.17%
YTD
-56.21%
QTD
-2.52%
Financial performance
How have Geron's revenue and profit performed over time
Revenue
$116.29M
Gross profit
$113.83M
Operating income
-$134.3M
Net income
-$139.02M
Gross margin
97.9%
Net margin
-119.5%
The operating margin has soared by 100% year-on-year and by 49% since the previous quarter
GERN's net margin has surged by 100% year-on-year and by 47% since the previous quarter
The revenue has soared by 51% from the previous quarter
The company's gross profit has surged by 50% QoQ
Price vs fundamentals
How does GERN's price correlate with its fundamentals
Growth
What is Geron's growth rate over time
Valuation
What is Geron stock price valuation
P/E
N/A
P/B
3.68
P/S
8.88
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
9.88
Geron's EPS has increased by 40% YoY and by 22% from the previous quarter
The P/B is 49% below the last 4 quarters average of 7.2 and 25% below the 5-year quarterly average of 4.9
Geron's equity has decreased by 22% YoY and by 4.3% from the previous quarter
The P/S is 99% below the 5-year quarterly average of 1640.5 and 98% below the last 4 quarters average of 540.0
The revenue has soared by 51% from the previous quarter
Efficiency
How efficient is Geron business performance
Geron's ROS has soared by 100% YoY and by 51% from the previous quarter
Geron's ROIC has soared by 62% YoY and by 41% from the previous quarter
The ROA has grown by 43% YoY and by 23% from the previous quarter
GERN's ROE is up by 29% year-on-year and by 15% since the previous quarter
Dividends
What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GERN.
Financial health
How did Geron financials performed over time
Geron's total assets is 91% higher than its total liabilities
The total liabilities has soared by 114% year-on-year but it has declined by 6% since the previous quarter
GERN's current ratio has soared by 114% year-on-year and by 42% since the previous quarter
GERN's debt is 8% smaller than its equity
GERN's debt has surged by 186% year-on-year
Geron's equity has decreased by 22% YoY and by 4.3% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.